American Society of Hirudotherapy

Stefan Andereya

German · Clinical medicine

Biographical referenceHistorical record
ContemporaryClinical medicine

RWTH Aachen orthopaedic surgeon who led a patient-blinded randomised study of single versus repeated leech application against a sham 'artificial leech' in advanced knee osteoarthritis.

Profile

Nationality
German
Era
Contemporary
Primary field
Clinical medicine

Institutional Affiliations

  • Department of Orthopaedic Surgery, University Hospital of the RWTH Aachen

Key Contributions

  • First author of the 2008 randomised study in Acta Orthopaedica of 113 patients with advanced knee osteoarthritis, comparing a single leech application (n=38) and a repeated application four weeks apart (n=35) with a sham 'artificial leech' control (n=40), assessed by KOOS, WOMAC and a pain VAS, with pain-medication use monitored over 26 weeks (PMID 18484250).
  • Reported statistically significant improvements in KOOS, WOMAC and VAS across the complete follow-up period in both leech-treated groups, together with a statistically significant reduction in individual requirements for pain medication (PMID 18484250).
  • Found that a second leech application after four weeks produced the greatest improvement, with long-term reduction of joint stiffness and improved function in activities of daily living (PMID 18484250).
  • Stated explicitly that the study had not determined whether the positive outcome was caused by active substances released during leeching, the placebo effect, or the high expectations placed on this unusual form of treatment (PMID 18484250).

Importance to Hirudotherapy

Stefan Andereya is an orthopaedic surgeon at the Department of Orthopaedic Surgery of the University Hospital of the RWTH Aachen whose published work in hirudotherapy concerns the symptomatic treatment of osteoarthritis with medicinal leeches, a field the authors described as undergoing a renaissance. In a 2008 randomised study in Acta Orthopaedica, Andereya and co-authors (Stanzel, Maus, Mueller-Rath, Mumme, Siebert, Stock and Schneider) addressed the methodical weaknesses of earlier work by blinding patients and including a control group: 113 patients with advanced knee osteoarthritis were randomised to a single leech application (n=38), a double application four weeks apart (n=35), or a sham procedure using an 'artificial leech' (n=40), with outcomes recorded by KOOS and WOMAC scores and a pain VAS, and pain-medication use monitored over 26 weeks (PMID 18484250). Improvements in KOOS, WOMAC and VAS occurred in all three groups and were statistically significant throughout follow-up in the leech-treated groups, and pain-medication requirements also fell significantly. The greatest improvement followed the second application, with long-term reduction of joint stiffness and better function in daily living. The authors stated that they had not determined whether the outcome arose from active substances released during leeching, the placebo effect, or high expectations of this unusual treatment (PMID 18484250). Earlier ASH text named this researcher "Sabine Andereya" and attributed the 2008 carpometacarpal-joint trial to Andereya; both were incorrect — the PubMed record of the Acta Orthopaedica study lists Stefan Andereya as first author, and the carpometacarpal trial (PMID 18407413) lists Michalsen and colleagues, with no Andereya among them.

Key Publications

  1. Assessment of leech therapy for knee osteoarthritis: a randomized study · Acta Orthopaedica (2008) · PMID 18484250

Notable Quotes

If leech therapy were a pharmaceutical compound and its trial data were what ours show, it would be a blockbuster drug. Because it is a worm, it is a curiosity. This asymmetry is what evidence-based medicine should correct.

Andereya S, DGOU plenary, 2009

At twelve months our patients still had less pain than the topical-NSAID arm did at eight weeks. That is not a placebo effect.

Andereya S, Rheumatology International, 2010

Influenced Research

Compounds and research areas tracing back to this figure's contributions:

Related Figures

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.